All In Biotech

Drug Trial Radar · NCT05281471

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 186 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

186

Planned (sponsor's estimate)

Start

Aug 31, 2022

Primary completion

Dec 2026

Study completion Dec 2027

Sponsor

Lead sponsor
Genelux CorporationIndustry
Sponsor type
Industry
Collaborators
GOG Foundation
First posted
Mar 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer. The phase II results also showed that the intra-peritoneal route of delivery was efficient in generating tumor cell killing and immune activation, and led to clinical reversal of platinum-resistance or refractoriness in this difficult-to-treat patient population.

Conditions

  • Platinum-resistant Ovarian Cancer
  • Platinum-refractory Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Cancer
  • High-grade Serous Ovarian Cancer
  • Endometrioid Ovarian Cancer
  • Ovarian Clear Cell Carcinoma

Interventions

  • olvimulogene nanivacirepvecBiological

    Olvi-Vec is an engineered oncolytic vaccinia virus

  • Platinum chemotherapy: carboplatin (preferred) or cisplatinDrug

    Administered according to local practice

  • Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicinDrug

    Administered according to local practice

  • Bevacizumab (or biosimilar)Drug

    Administered according to local practice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) by RECIST 1.1 in the Intention-to-Treat (ITT) population (all randomized participants regardless of whether they received any dose of treatment)Time frame: From date of randomization up to 12 months

Locations

33 sites in 1 country. Site status is shown where the registry gives one.

  • The University of South Alabama, Mitchell Cancer Institute

    Mobile, Alabama · Recruiting

  • University of Arizona Cancer Center

    Tucson, Arizona · Recruiting

  • City of Hope

    Duarte, California · Recruiting

  • UC San Diego Health - Moores Cancer Center

    La Jolla, California · Recruiting

  • Hoag Gynecologic Oncology

    Newport Beach, California · Recruiting

  • UCI Health Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • AdventHealth Cancer Institute

    Orlando, Florida · Recruiting

  • Sarasota Memorial Healthcare System

    Sarasota, Florida · Recruiting

  • Women's Cancer Associates with Women's Care Florida

    St. Petersburg, Florida · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • Indiana University Simon Comprehensive Cancer Center

    Indianapolis, Indiana · Recruiting

  • Holy Cross Hospital

    Silver Spring, Maryland · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Mercy Hospital St. Louis

    St Louis, Missouri · Recruiting

  • Women's Cancer Center of Nevada

    Las Vegas, Nevada · Recruiting

  • Center of Hope

    Reno, Nevada · Recruiting

  • Stony Brook Cancer Center

    Stony Brook, New York · Recruiting

  • Levine Cancer Institute

    Charlotte, North Carolina · Recruiting

  • East Carolina University

    Greenville, North Carolina · Recruiting

  • Atrium Health Wake Forest Baptist, Comprehensive Cancer Center

    Winston-Salem, North Carolina · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • OhioHealth Research Institute

    Columbus, Ohio · Recruiting

  • Kettering Health

    Kettering, Ohio · Recruiting

  • ProMedica Flower Hospital

    Sylvania, Ohio · Recruiting

  • Oklahoma University Health Stephenson Cancer Center

    Oklahoma City, Oklahoma · Recruiting

  • AHN West Penn Hospital

    Pittsburgh, Pennsylvania · Recruiting

  • Hollings Cancer Center

    Charleston, South Carolina · Recruiting

  • Erlanger Health, Inc.

    Chattanooga, Tennessee · Recruiting

  • Baylor College of Medicine

    Houston, Texas · Recruiting

  • University of Texas Science Center at Houston, McGovern Medical School

    Houston, Texas · Recruiting

  • Providence Sacred Heart Medical Center & Children's Hospital

    Spokane, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.